Results
1
-
10
of
23
<
1
2
3
>
Bilen O; Ballantyne CM.
Bempedoic Acid (ETC-1002): an Investigational Inhibitor of ATP Citrate Lyase.
,
Current atherosclerosis reports
[PubMed: 27663902]
[DOI: 10.1007/s11883-016-0611-4]
Norata GD; Ballantyne CM; Catapano AL.
New therapeutic principles in dyslipidaemia: focus on LDL and Lp(a) lowering drugs.
,
European heart journal
[PubMed: 23509227]
[DOI: 10.1093/eurheartj/eht088]
Pinkosky SL; Filippov S; Srivastava RA; Naples M; Adeli K; Newton RS; Hanselman JC; Bradshaw CD; Hurley TR; Cramer CT; Spahr MA; Brant AF; Houghton JL; Baker C.
AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism.
,
Journal of lipid research
[DOI: 10.1194/jlr.M030528]
Penson P; McGowan M; Banach M.
Evaluating bempedoic acid for the treatment of hyperlipidaemia.
,
Expert opinion on investigational drugs
[DOI: 10.1080/13543784.2017.1280458]
Ballantyne CM; McKenney JM; MacDougall DE; Margulies JR; Robinson PL; Hanselman JC; Lalwani ND.
Effect of ETC-1002 on Serum Low-Density Lipoprotein Cholesterol in Hypercholesterolemic Patients Receiving Statin Therapy.
,
The American journal of cardiology
[DOI: 10.1016/j.amjcard.2016.03.043]
Samsoondar JP; Burke AC; Sutherland BG; Telford DE; Sawyez CG; Edwards JY; Pinkosky SL; Newton RS; Huff MW.
Prevention of Diet-Induced Metabolic Dysregulation, Inflammation, and Atherosclerosis in <i>Ldlr<sup>-/-</sup></i> Mice by Treatment With the ATP-Citrate Lyase Inhibitor Bempedoic Acid.
,
Arteriosclerosis, thrombosis, and vascular biology
[DOI: 10.1161/ATVBAHA.116.308963]
Burke AC; Huff MW.
ATP-citrate lyase: genetics, molecular biology and therapeutic target for dyslipidemia.
,
Current opinion in lipidology
[DOI: 10.1097/MOL.0000000000000390]
Thompson PD; Rubino J; Janik MJ; MacDougall DE; McBride SJ; Margulies JR; Newton RS.
Use of ETC-1002 to treat hypercholesterolemia in patients with statin intolerance.
,
Journal of clinical lipidology
[DOI: 10.1016/j.jacl.2015.03.003]
Stein EA; Raal FJ.
Lipid-Lowering Drug Therapy for CVD Prevention: Looking into the Future.
,
Current cardiology reports
[DOI: 10.1007/s11886-015-0659-8]
Lemus HN; Mendivil CO.
Adenosine triphosphate citrate lyase: Emerging target in the treatment of dyslipidemia.
,
Journal of clinical lipidology
[DOI: 10.1016/j.jacl.2015.01.002]
<
1
2
3
>